“Enough. I resigned from #Celltex Therapeutics on & effective 2/28/2012. I am preparing timely, lengthy, pointed comments on the whole matter.” This is a Tweet this week from Glenn McGee, the embattled bioethicist who moved from the American Journal of Bioethics (AJOB) to a stem cell company in Texas.

“Enough. I resigned from #Celltex Therapeutics on & effective 2/28/2012. I am preparing timely, lengthy, pointed comments on the whole matter.” This is a Tweet this week from Glenn McGee, the embattled bioethicist who moved from the American Journal of Bioethics (AJOB) to a stem cell company in Texas.

Dr McGee had been savagely criticised by some of his bioethics colleagues for taking a job as  president of ethics and strategic initiatives with Celltex, a controversial company which licenses technology from a South Korean company, RNL Bio, which offers adult stem cell treatments with patients’ own fat cells.

These treatments are considered experimental and have not been approved for routine use by the US Food and Drug Administration or by regulators in South Korea, according to Nature. McGee’s critics also asked whether his new job posed a conflict of interest with his responsibilities at AJOB  and whether the appointment of his wife, Summer Johnson McGee, as co-editor, had been prudent. 

Michael Cook
conflict of interest
professional standards
stem cells